SCHEMBL447973

SCHEMBL447973

CCCCCC=C(C#N)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.55
PPARG P37231 7/20 0.41
PPARA Q07869 2/20 0.41
TRPA1 O75762 1/20 0.41
FBP1 P09467 1/20 0.41
POLB P06746 2/20 0.41
GMNN O75496 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DUSP3 P51452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9361015 1.00 EP300 (0.55) EP300PPARGPPARATRPA1FBP1
SCHEMBL1602959 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL423102 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL154904 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL7568098 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL1274680 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL973729 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL3149613 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL29047 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1
SCHEMBL142755 0.98 EP300 (0.58) EP300PPARGPPARATRPA1FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104704-A1 A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE FUNDACIÓ INSTITUT DE INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) 2026-05-21 WO claimed
EP-4744687-A1 A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE Aesculap AG (DE) 2026-05-20 EP claimed
EP-3579890-B1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FEMASYS INC (US) 2025-06-18 EP claimed
US-20220025552-A1 METHOD OF PRODUCING POLY(ALKYL CYANOACRYLATE) BASED NANO/MICROFIBERS AND USES THEREOF CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN (DE) 2022-01-27 US claimed
EP-3941989-A1 CYANOACRYLATE ADHESIVE COMPOSITION Henkel AG & Co. KGaA (DE) 2022-01-26 EP claimed
US-20220002590-A1 Cyanoacrylate Adhesive Composition HENKEL AG & CO KGAA (DE) 2022-01-06 US claimed
EP-3894617-A1 METHOD OF PRODUCING POLY(ALKYL CYANOACRYLATE) BASED NANO/MICROFIBERS AND USES THEREOF Charité - Universitätsmedizin Berlin (DE) 2021-10-20 EP claimed
WO-2020191510-A1 CYANOACRYLATE ADHESIVE COMPOSITION HENKEL AG & CO. KGAA (DE) 2020-10-01 WO claimed
EP-3666940-A1 METHOD OF PRODUCING POLY(ALKYL CYANOACRYLATE) BASED NANO/MICROFIBERS AND USES THEREOF Charité - Universitätsmedizin Berlin (DE) 2020-06-17 EP claimed
US-9752049-B2 Optically transparent, superhydrophobic, biocompatible thin film coatings and methods for producing same UT-BATTELLE, LLC (US) 2017-09-05 US claimed
EP-2511355-B1 Cyanoacrylate adhesive with improved water resistance HENKEL IRELAND LTD (DE) 2013-10-23 EP claimed
EP-1100380-B1 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTHCARE (US) 2011-11-02 EP claimed
EP-1360257-B1 CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS LOCTITE R & D LTD (IE) 2007-07-25 EP claimed
US-6977278-B1 Cyanoacrylate compositions curable to flexible polymeric materials LOCTITE (R&D) LTD. (IE) 2005-12-20 US claimed
WO-2004024467-A2 SURFACE-MOUNTING SYSTEM LOCTITE (R & D) LIMITED (IE) 2004-03-25 WO claimed
EP-1360257-A1 CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS Loctite (R & D) Limited (IE) 2003-11-12 EP claimed
WO-2003015743-A1 IMMUNISATION BY MEANS OF THE LOCAL IMPLANTATION OF ANTIGENS WHICH ARE IRREVERSIBLY FIXED TO A BIOADHERENT BOUAZIZ ADAM (FR) 2003-02-27 WO claimed
WO-2002053666-A1 CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS LOCTITE (R & D) LIMITED (IE) 2002-07-11 WO claimed
US-20020065314-A1 COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH S.N. BIOTECH, INC. 2002-05-30 US claimed
US-3940362-A Cross-linked cyanoacrylate adhesive compositions JOHNSON & JOHNSON (US) 1976-02-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065314-A1 COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH AREG, NGF, HDGF EP300 488/4885PPARG 382/4885PPARA 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.